The ability to determine the non-transferrin-bound iron and total iron in the human placenta using high-performance liquid chromatography method
Abstract
Iron is one of the most important microelements in the human body. It is a component of haemoglobin, which transports oxygen to all cells in the organism. It is also used in the synthesis of myelin, neurotrans-mitters, and DNA and transfers electrons in biochemical reactions. Iron is also responsible for regular development of the foetus’ central nervous system. Furthermore, as a result of Fenton reactions, iron leads to formation of toxic free radicals. The existence of non-transferrin-bound iron (NTBI) and its part desfer-rioxamine-chelatable iron (DCI) can be used to assess this element in the body. The placenta is an organ transition that is formed during pregnancy in the female organism. It has a dense web of blood vessels in which dynamic exchange of blood between mother and foetus takes place. As a result, a fraction of NTBI may be present in the placenta. The main goal of this work was to develop a method for determining total iron and desferrioxamine-chelatable iron in solid tissues - the human placenta.
Keywords: desferrioxamine chelatable iron (DCI)Desferalferrioxamine (FO)high-performance liquid chromatography (HPLC)placentatotal iron
References
- Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005; 202(2): 199–211.
- Escobar-Morreale HF. Iron metabolism and the polycystic ovary syndrome. Trends Endocrinol Metab. 2012; 23(10): 509–515.
- Koba M, Słomka A, Bączek T, et al. Ability to determine the desferrioxamine-chelatable iron fractions of nontransferrin-bound iron using HPLC. J Sep Sci. 2013; 36(4): 665–669.
- Slomka A, Piotrowska K, Koba M, et al. Non-Transferrin Bound Iron - Determination in Biological Material and Clinical Implications. Current Pharmaceutical Analysis. 2011; 7(4): 280–285.
- Marzocchi B, Perrone S, Paffetti P, et al. Nonprotein-bound iron and plasma protein oxidative stress at birth. Pediatr Res. 2005; 58(6): 1295–1299.
- Buonocore G, Perrone S, Longini M, et al. Non protein bound iron as early predictive marker of neonatal brain damage. Brain. 2003; 126(Pt 5): 1224–1230.
- Pazirandeh, S. et al. (2012) Overview of dietary trace minerals. Wolters Kluwer Health.
- Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol. 2011; 4(3): 177–184.
- Aggett PJ, Agostoni C, Axelsson I, et al. Iron metabolism and requirements in early childhood: do we know enough?: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2002; 34(4): 337–345.
- Słomka A, Żekanowska E, Piotrowska K, et al. Iron metabolism and maternal-fetal iron circulation. Postepy Hig Med Dosw. 2012; 66: 876–887.
- Logan S, Martins S, Gilbert R. Iron therapy for improving psychomotor development and cognitive function in children under the age of three with iron deficiency anaemia. Cochrane Database Syst Rev. 2001(2): CD001444.
- Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J. 2011; 434(3): 365–381.
- Słomka A, Włodarczyk W, Żekanowska E. Udział żelaza niezwiązanego z transferryną w patofizjologii chorób człowieka. Przegląd Med Uniw Rzesz i NIL w Warszawie Rzeszów. 2011; 1: 101–107.
- Buonocore G, Perrone S, Longini M, et al. Non protein bound iron as early predictive marker of neonatal brain damage. Brain. 2003; 126(Pt 5): 1224–1230.
- Dorrepaal CA, Berger HM, Benders MJ, et al. Nonprotein-bound iron in postasphyxial reperfusion injury of the newborn. Pediatrics. 1996; 98(5): 883–889.